the Influence of General Anesthesia on Tumor Metastasis and Recurrence

Tumor Recurrence and Metastasis Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02474511
• Other study ID #: ????[2015]058K
• Status: Recruiting
• Phase: N/A
• First received: June 14, 2015
• Last updated: June 16, 2015
• Start date: June 2015
• Est. completion date: April 2019

Study information

• Verified date: June 2015
• Source: RenJi Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study was to investigate whether general anesthesia will affect the postoperative recurrence and metastasis of malignant tumor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: April 2019
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• ASA I - III Primary liver cancer tumor is single and diameter is less than 3 centimeter There is no major vascular invasion phenomenon, no lymph nodes or extrahepatic metastases The Child - Pugh belong to type A or type B

Exclusion Criteria:

• Had a history of liver surgery (including radiofrequency ablation) Severe disease of heart, lung, kidney, the immune system INR > 1.5 or platelet count is less than 45000 cells/mm3 History of opioid addiction Metastatic liver tumors Not sure of primary liver cancer Don't agree to participate in this experiment

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Recurrence
• Tumor Recurrence and Metastasis

Intervention

Other:
• general anesthesia and local anesthesia
the patient received generalanesthesia and local anesthesia randomly

Locations

Country	Name	City	State
China	Shanghai Renji Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RenJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with tumor recurrence and metastasis	Follow-up of patients with tumor recurrence and metastasis after Radiofrequency ablation to 3 years	3 years	No